EP1356079A4 - Modulierung des srebp-wegs mit hisrs als zielmolekül - Google Patents

Modulierung des srebp-wegs mit hisrs als zielmolekül

Info

Publication number
EP1356079A4
EP1356079A4 EP02713405A EP02713405A EP1356079A4 EP 1356079 A4 EP1356079 A4 EP 1356079A4 EP 02713405 A EP02713405 A EP 02713405A EP 02713405 A EP02713405 A EP 02713405A EP 1356079 A4 EP1356079 A4 EP 1356079A4
Authority
EP
European Patent Office
Prior art keywords
hisrs
targeting
srebp pathway
pathway modulation
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02713405A
Other languages
English (en)
French (fr)
Other versions
EP1356079A2 (de
Inventor
Cynthia Seidel-Dugan
Lisa C Kadyk
Felipa A Mapa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of EP1356079A2 publication Critical patent/EP1356079A2/de
Publication of EP1356079A4 publication Critical patent/EP1356079A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
EP02713405A 2001-01-12 2002-01-11 Modulierung des srebp-wegs mit hisrs als zielmolekül Withdrawn EP1356079A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26156901P 2001-01-12 2001-01-12
US261569P 2001-01-12
PCT/US2002/001045 WO2002055663A2 (en) 2001-01-12 2002-01-11 Srebp pathway modulation through targeting hisrs

Publications (2)

Publication Number Publication Date
EP1356079A2 EP1356079A2 (de) 2003-10-29
EP1356079A4 true EP1356079A4 (de) 2005-10-19

Family

ID=22993896

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02713405A Withdrawn EP1356079A4 (de) 2001-01-12 2002-01-11 Modulierung des srebp-wegs mit hisrs als zielmolekül

Country Status (4)

Country Link
EP (1) EP1356079A4 (de)
JP (1) JP2004524021A (de)
AU (1) AU2002245257A1 (de)
WO (1) WO2002055663A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5771142B2 (ja) 2008-06-11 2015-08-26 エータイアー ファーマ， インコーポレイテッド チロシル−ｔＲＮＡシンテターゼポリペプチドの血小板新生活性
WO2009158649A1 (en) 2008-06-26 2009-12-30 Atyr Pharma, Inc. Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities
WO2010099477A2 (en) 2009-02-27 2010-09-02 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
DK3255146T3 (da) 2009-03-16 2019-08-19 Pangu Biopharma Ltd Præparater og fremgangsmåder omfattende histidyl-tRNA-synthetasesplejsningsvarianter med ikke-kanoniske biologiske aktiviteter
US20100310576A1 (en) 2009-03-31 2010-12-09 Adams Ryan A COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
CA2783731C (en) 2009-12-11 2018-03-27 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating inflammation
NZ603811A (en) 2010-07-12 2015-03-27 Atyr Pharma Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
KR20130102534A (ko) 2010-07-12 2013-09-17 에이티와이알 파마, 인코포레이티드 히스티딜­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
EP2593125B1 (de) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von glycyl-trna-synthetasen
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
CA2858613A1 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
KR20140123571A (ko) 2012-02-16 2014-10-22 에이티와이알 파마, 인코포레이티드 자가면역 및 염증성 질환의 치료를 위한 히스티딜­ｔｒｎａ 신테타제
AU2014233436B2 (en) 2013-03-15 2019-12-05 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
WO2015027171A1 (en) * 2013-08-23 2015-02-26 Quintiles Transnational Corporation Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (srebp) pathway
JP2020517638A (ja) 2017-04-20 2020-06-18 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076308A1 (en) * 1999-06-14 2000-12-21 Exelixis, Inc. Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076308A1 (en) * 1999-06-14 2000-12-21 Exelixis, Inc. Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism

Also Published As

Publication number Publication date
AU2002245257A1 (en) 2002-07-24
WO2002055663A2 (en) 2002-07-18
JP2004524021A (ja) 2004-08-12
WO2002055663A3 (en) 2002-09-19
EP1356079A2 (de) 2003-10-29

Similar Documents

Publication Publication Date Title
EP1356079A4 (de) Modulierung des srebp-wegs mit hisrs als zielmolekül
EP1443963A4 (de) Antikörper-targeting-verbindungen
SG102048A1 (en) Fridge-freezer
IL157374A0 (en) Capsule
EP1446418A4 (de) Auf integrin zielende verbindungen
EP1420747A4 (de) Benzochuinonansamycine
EP1377187A4 (de) Verbesserter rucksack
EP1463127A4 (de) Fotodiode
GB0119665D0 (en) Conjugates
PL365734A1 (en) Substituted arylketones
GB0126781D0 (en) Modulation
HUP0105406D0 (en) Ovel compounds
TW584302U (en) Center-adjustment assembling device
EP1392204A4 (de) Bifunktionale energieumkehrbare acylzusammensetzungen
GB0203683D0 (en) PAK-GFP Construct
GB0124150D0 (en) Housing
AU143630S (en) Rodent baitstation assembly
GB2382025B (en) Balanced non-swerve castor
AU3099P (en) Gan01 Cordyline fruticosa
AU2634P (en) Darzing Pinelime Zingiber spectabile
IL146586A0 (en) Orthopedic targeting device
GB0123748D0 (en) Laser field
GB0126772D0 (en) Modulation
GB0126771D0 (en) Modulation
GB0126808D0 (en) Modulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030731

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050905

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 48/00 B

Ipc: 7A 61K 39/00 B

Ipc: 7C 12Q 1/25 B

Ipc: 7G 01N 33/92 A

17Q First examination report despatched

Effective date: 20051206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070731